

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai MicroPort MedBot (Group) Co., Ltd.**

**上海微创医疗机器人(集团)股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2252)**

- (1) POLL RESULTS OF THE 2025 EXTRAORDINARY GENERAL MEETING HELD ON 25 NOVEMBER 2025;**
- (2) APPOINTMENT OF DIRECTORS AND THE CHAIRPERSON OF THE BOARD;**
- (3) AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE RULES OF PROCEDURE FOR THE GENERAL MEETING OF SHAREHOLDERS;**
- (4) CHANGE IN BOARD COMMITTEES; AND**
- (5) CHANGE IN AUTHORISED REPRESENTATIVE**

References are made to the announcement (the “**Announcement**”) regarding the changes in Directors and the notice (the “**EGM Notice**”) of the 2025 extraordinary general meeting (the “**EGM**”), and the circular (the “**Circular**”) of Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”) dated 5 November 2025. Capitalised terms used herein shall, unless otherwise defined, have the same meanings as those defined in the Announcement and the Circular.

The Board is pleased to announce that the Company convened and held the EGM at 1601 Zhangdong Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, PRC on Tuesday, 25 November 2025. The proposed resolutions as set out in the EGM Notice were duly passed by way of poll at the EGM.

## **POLL RESULTS OF THE EGM**

As at the date of the EGM, the total number of shares of the Company in issue was 1,031,330,331, which entitled the holders to attend the EGM and vote for or against or abstain from voting on the resolutions proposed thereat. The Shareholders and proxies of Shareholders attending the EGM held a total of 599,487,480 voting shares of the Company, representing approximately 58.1% of the total number of issued shares of the Company as at the date of the EGM.

The poll results in respect of the resolutions proposed at the EGM were as follows:

<b>ORDINARY RESOLUTIONS</b>		<b>Number of Votes and Percentage of Total Number of Votes</b>		
		<b>FOR</b>	<b>AGAINST</b>	<b>ABSTAIN</b>
1.	To consider and approve the appointment of Dr. Zhaohua Chang as a non-executive director of the Company, and to authorise the Board to fix his remuneration.	595,691,485 99.366793%	3,794,494 0.632957%	1,501 0.000250%
2.	To consider and approve the appointment of Mr. Hiroshi Shirafuji as a non-executive director of the Company, and to authorise the Board to fix his remuneration.	596,684,617 99.532457%	2,801,362 0.467293%	1,501 0.000250%
3.	To consider and approve the appointment of Mr. Norihiro Ashida as a non-executive director of the Company, and to authorise the Board to fix his remuneration.	596,684,617 99.532457%	2,801,362 0.467293%	1,501 0.000250%
4.	To consider and approve the appointment of Ms. Min Liang as a non-executive director of the Company, and to authorise the Board to fix her remuneration.	597,235,449 99.624341%	2,250,530 0.375409%	1,501 0.000250%
5.	To consider and approve the appointment of Mr. Jonathan H. Chou as an independent non-executive director of the Company, and to authorise the Board to fix his remuneration.	597,885,830 99.732830%	1,600,150 0.266920%	1,500 0.000250%
6.	To consider and approve the appointment of Dr. Guoen Liu as an independent non-executive director of the Company, and to authorise the Board to fix his remuneration.	597,885,829 99.732830%	1,600,150 0.266920%	1,501 0.000250%
<b>SPECIAL RESOLUTION</b>		<b>Number of Votes and Percentage of Total Number of Votes</b>		
		<b>FOR</b>	<b>AGAINST</b>	<b>ABSTAIN</b>
7.	To consider and approve the proposed amendments to the Articles of Association of the Company and the Rules of Procedure for the General Meeting of Shareholders.	599,485,979 99.999750%	0 0.000000%	1,501 0.000250%

In respect of each of the above ordinary resolutions numbered 1 to 6, as more than half of the voting rights represented by the Shareholders (including their proxies) attending the EGM were cast in favour of each of these resolutions, all these resolutions were duly passed as ordinary resolutions at the EGM.

In respect of the above special resolution numbered 7, as more than two-thirds of the voting rights represented by the Shareholders (including their proxies) attending the EGM were cast in favour of the resolution, the resolution was duly passed as a special resolution at the EGM.

The EGM was convened by the Board. Mr. Hongbin Sun, a non-executive Director and the chairperson of the Board, was the chairperson of the EGM and presided over the EGM.

The executive Directors, Dr. Chao He, Mr. Yu Liu and Ms. Cong Fang; the non-executive Directors, Mr. Hongbin Sun and Mr. Chen Chen; and the independent non-executive Directors, Dr. Minghua Li, Mr. Haisong Yao and Mr. Wai Man Chung, attended the EGM either in person or by online conferencing.

Save as disclosed, as at the date of the EGM, (i) there were no shares of the Company entitling the Shareholders to attend and abstain from voting in favour of the resolutions proposed at the EGM pursuant to Rule 13.40 of the Listing Rules; (ii) none of the Shareholders were required under the Listing Rules to abstain from voting at the EGM; and (iii) none of the Shareholders had stated their intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the EGM.

Computershare Hong Kong Investor Services Limited, the Company's branch share registrar in Hong Kong, acted as the scrutineer for vote-taking at the EGM.

## **APPOINTMENT OF DIRECTORS AND THE CHAIRPERSON OF THE BOARD**

The Board is pleased to announce that:

- Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Min Liang have been appointed as non-executive Directors with effect from the conclusion of the EGM;
- Dr. Guoen Liu and Mr. Jonathan H. Chou have been appointed as independent non-executive Directors with effect from the conclusion of the EGM; and
- Dr. Zhaohua Chang has been further appointed as the chairperson of the Board with effect from 25 November 2025.

Please refer to the Announcement and the Circular for the biographical details of each of Dr. Chang, Mr. Shirafuji, Mr. Ashida, Ms. Liang, Dr. Liu and Mr. Chou and the information required to be disclosed under Rule 13.51(2) of the Listing Rules. Dr. Chang resigned as the chairperson of the board of directors and a non-executive director of MicroPort NeuroScientific Corporation (a company listed on the Stock Exchange, stock code: 02172) on 14 November 2025. Ms. Liang ceased to act as the chairperson of the board of supervisors of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (上海微創心脈醫療科技(集團)股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 688016) with effect from 14 November 2025. Save as disclosed above, each

of Dr. Chang, Mr. Shirafuji, Mr. Ashida, Ms. Liang, Dr. Liu and Mr. Chou confirmed that there is no other change in their biographical details between the publication date of the Announcement and the Circular and the date of this announcement.

Each of Dr. Liu and Mr. Chou has confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) that save as disclosed in the Announcement and the Circular, he has no other past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected persons (as defined under the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence as at the date of his appointment.

The Company has entered into letters of appointment with Dr. Chang, Mr. Shirafuji, Mr. Ashida, Ms. Liang, Dr. Liu and Mr. Chou. Each of them will hold office until the end of the second session of the Board.

## **PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE RULES OF PROCEDURE FOR THE GENERAL MEETING OF SHAREHOLDERS**

The Proposed Amendments to the Articles of Association and the proposed amendments to the Rules of Procedure for the General Meeting of Shareholders have been approved by the Shareholders at the EGM by way of a special resolution and has become effective on 25 November 2025. Details of the Proposed Amendments to the Articles of Association and the proposed amendments to the Rules of Procedure for the General Meeting of Shareholders are contained in “Appendix — Proposed Amendments to the Articles of Association and the Rules of Procedure for the General Meeting of Shareholders” in the Circular.

## **CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board hereby announces the following changes in composition of board committees from 25 November 2025:

- The audit committee consists of Mr. Jonathan H. Chou and Mr. Wai Man Chung, being independent non-executive Directors, and Mr. Norihiro Ashida, being a non-executive Director, and Mr. Jonathan H. Chou will act as the chairperson;
- The remuneration and appraisal committee consists of Dr. Guoen Liu and Mr. Jonathan H. Chou, being independent non-executive Directors, and Mr. Norihiro Ashida, being a non-executive Director, and Dr. Guoen Liu will act as the chairperson;
- The nomination committee consists of Mr. Haisong Yao and Mr. Wai Man Chung, being independent non-executive Directors, and Ms. Min Liang, being a non-executive Director, and Mr. Haisong Yao will act as the chairperson;

- The strategy and development committee consists of Dr. Guoen Liu, being an independent non-executive Director, Mr. Hiroshi Shirafuji, being a non-executive Director, and Dr. Chao He, being an executive Director, and Dr. Guoen Liu will act as the chairperson; and
- The commercialisation committee consists of Mr. Hiroshi Shirafuji and Mr. Chen Chen, being non-executive Directors, Mr. Yu Liu, being an executive Director, and Ms. Min Liang, being a non-executive Director, and Mr. Hiroshi Shirafuji will act as the chairperson.

## **CHANGE IN AUTHORISED REPRESENTATIVE**

The Board hereby announces that Mr. Hongbin Sun ceased to act as an authorised representative (“**Authorised Representative**”) of the Company for the purpose of Rule 3.05 of the Listing Rules, and Dr. Zhaohua Chang will replace Mr. Hongbin Sun as the Authorised Representative of the Company with effect from 25 November 2025.

By order of the Board  
**Shanghai MicroPort MedBot (Group) Co., Ltd.**  
**Dr. Zhaohua Chang**  
*Chairperson*

Shanghai, China, 25 November 2025

*As at the date of this announcement, the executive Directors are Dr. Chao He and Mr. Yu Liu, the non-executive Directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive Directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.*